Array BioPharma, Inc. (NASDAQ:ARRY) announced that it has reached a definitive agreement with Novartis International Pharmaceutical Ltd. to regain full worldwide rights to binimetinib, a MEK inhibitor in three Phase 3 trials. This agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline PLC on April 22, 2014, which are expected in the first half of 2015, and remain subject to regulatory … Continue reading Why Need to Watch: Array BioPharma, Inc. (NASDAQ:ARRY), Hewlett-Packard Company (NYSE:HPQ), Polycom, Inc. (NASDAQ:PLCM), Endurance International Group (NASDAQ:EIGI), Diamond Offshore Drilling (NYSE:DO)